srch

1 day ago · this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995, as amended, including, without limitation, express or implied...

30.09.2021 · this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for blueprint medicines' current or future approved drugs and drug candidates, including timelines for …

Read the press release announcing the expansion of the FDA label for AYVAKIT into advanced SM here. AYVAKIT received its initial approval from ...

Oct 21, 2021 · Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Except as required by law, Blueprint Medicines expressly disclaims any obligation to update the information contained in such press releases after the date of their issuance.

14.07.2020 · This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the collaboration agreement among Blueprint Medicines, Roche and

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is ...

30.12.2021 · Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995, as amended, including, without limitation, express or implied statements regarding plans, strategies, timelines and expectations for blueprint medicines' current or future approved drugs and drug candidates, including …

View the latest Blueprint Medicines Corp. ... 12/09/21; Press Release ... Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with ...

1 day ago · this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995, as amended, including, without limitation, express or implied...

09.11.2021 · this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for blueprint medicines'current or future approved drugs and drug candidates, including timelines for …

29.11.2021 · this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995, as amended, including, without …

PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today ... Read the press release announcing the expansion of the FDA label for ...

Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 28, ...

Press Release November 29, 2021 ... Through this acquisition, Blueprint Medicines will add LNG-451, an oral precision therapy in development for the ...

1 day ago · Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a ...

21.10.2021 · Except as required by law, Blueprint Medicines expressly disclaims any obligation to update the information contained in such press releases after the date of their issuance. Investor contact Kristin Hodous Senior Manager, Investor Relations investors@blueprintmedicines.com 617.714.6674 Media contact Andrew Law Associate Director, Product Communications …

Stay up to date with all latest press releases from Blueprint Medicines Corporation (BPMC).

31.12.2021 · Any forward-looking statements contained in this press release represent Blueprint Medicines’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

09.11.2021 · Blueprint Medicines Corporation (NASDAQ: BPMC) and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and ...

View the latest Blueprint Medicines (BPMC) company-issued press releases.

Jul 14, 2020 · This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the collaboration agreement among Blueprint Medicines, Roche and

1 dag siden · This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidates, including timelines …

Jul 28, 2021 · This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the research collaboration between Blueprint Medicines and The University of Texas MD Anderson Cancer Center; plans and timelines for the research and development of BLU-222; the potential benefits of BLU-222 in treating patients; and Blueprint Medicines' strategy, goals and anticipated milestones ...